CCL2 and diabetic kidney disease: Targeting the chemokine MCP-1/CCL2 or its receptor CCR2 by different means (neutralizing antibodies, receptor antagonists, inhibitors, DNA vaccines, mutant genes or enantiomeric RNA oligonucleotides (l-RNA aptamer )) decreased albuminuria, kidney injury and inflammation and preserved kidney function in experimental kidney injury, including DKD [71,72,73].